IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11931399 B1

PDFFull Text
Date of Patent:
Mar. 19, 2024

Filed:

Dec. 12, 2022

Compositions and methods for dengue virus chimeric constructions in vaccines

Applicant:

Takeda Vaccines, Inc., Cambridge, MA (US);

Inventors:

Dan T. Stinchcomb, Enumclaw, WA (US);

Claire Kinney, Fort Collins, CO (US);

Richard M. Kinney, Fort Collins, CO (US);

Jill A. Livengood, Fort Collins, CO (US);

Assignee:

Takeda Vaccines, Inc., Cambridge, MA (US);

Attorneys:

Honigman LLP

Harold H. Fox

Jonathan P. O'Brien

Primary Examiner:

Stacy B Chen

Int. Cl.
CPC ...
A61K 39/12 (2006.01); A61K 31/7048 (2006.01); A61K 31/713 (2006.01); A61K 38/16 (2006.01); C07K 14/005 (2006.01); C07K 14/18 (2006.01); C07K 19/00 (2006.01); C12N 15/09 (2006.01); C12N 15/861 (2006.01); A61K 39/00 (2006.01); A61P 31/14 (2006.01);
U.S. Cl.
CPC ...
A61K 38/162 (2013.01); A61K 31/7048 (2013.01); A61K 31/713 (2013.01); A61K 39/12 (2013.01); C07K 14/005 (2013.01); C07K 14/1825 (2013.01); C07K 19/00 (2013.01); C12N 15/09 (2013.01); C12N 15/8613 (2013.01); A61K 2039/5254 (2013.01); A61K 2039/70 (2013.01); A61P 31/14 (2018.01); C07K 2319/00 (2013.01); C12N 2770/24122 (2013.01); C12N 2770/24134 (2013.01); C12N 2770/24141 (2013.01); C12N 2770/24143 (2013.01); C12N 2770/24162 (2013.01); Y02A 50/30 (2018.01);
Abstract

Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.

Find Patent Forward Citations

Loading…